First-in-class programmes on biologically relevant and disease-driving modes of action
QUANTRO´s transcriptomic screenings identify innovative first-in-class chemistry, creating functionally validated hit libraries. Selected compounds pass further evaluation, then progress to hit-to-lead optimisation, onward characterisation, and ultimately clinical development.
The pipeline
Programmes and current stage
QUANTRO´s proprietary pipeline is created from functionally validated hit libraries discovered by our proprietary transcriptomic drug discovery engine.
All internal and partnered programmes are based on proprietary chemistry of hits that are functionally validated with confirmed, target-specific transcriptional response.
Pipeline chart, 4 programmes against a five-stage scale running from target and assay through hit discovery, hit validation, hit-to-lead and lead optimisation. Hippo pathway, YAP/TEAD, Lead programme: Hit-to-lead. MYC, Priority programme: Hit validation. Boehringer Ingelheim collaboration, Selected oncology targets: Hit validation. Pipeline expansion, Additional transcriptional targets: Assay development.
Functionally validated TEAD inhibitors advancing through hit-to-lead optimisation
QUANTRO has built a proprietary, functionally validated hit library of potent, selective TEAD inhibitors. The most advanced hit clusters are progressing through hit-to-lead optimisation, including covalent TEAD inhibitors with binding to TEAD1 confirmed by co-crystal structure.
Proprietary, functionally validated hit library
QUANTRO has created a proprietary library of MYC hits functionally validated by SLAMseq® and confirmed across the full transcriptome. The hits produce a clean, selective effect on the MYC transcriptional fingerprint and include a mechanistically novel series. Further hit generation and validation are ongoing.
Active under the Boehringer Ingelheim collaboration
New targets in oncology, autoimmunity and inflammation
Partnered programme
Oncology collaboration with Boehringer Ingelheim
Since 2022, QUANTRO and Boehringer Ingelheim have been working together to discover first-in-class compounds against selected cancer-associated transcription factors.
2022
Collaboration launched
2024
Technical proof of concept
2025
Two-year extension
~€500 million estimated deal value
Success-based milestone potential
The collaboration applies QUANTRO’s platform to high-throughput screening and functional hit validation. After technical proof of concept and a major screening campaign, the partners extended the programme in October 2025. QUANTRO retains its platform and internal programmes outside the collaboration.
Pipeline expansion
Expanding QUANTRO’s target space
QUANTRO is building indication-focused multiplex panels that combine new targets with established transcriptional fingerprints across oncology, autoimmunity and inflammation.
Indication map. Indication panels are marked on a human figure, each combining new transcriptional targets with established ones: breast, lung, ovarian, neuroblastoma, prostate, lymphoma & b-cell autoimmunity. Select any indication below for its target list.
Partnering
QUANTRO is your strategic partner of choice for transcriptomic drug discovery
Pioneering time-resolved transcriptomics, we identify first-in-class assets against your most difficult and undruggable targets. Reliably, with precision and speed, we open access to the high-value, largely unexploited target space of transcription factors.